FindTrial
Sign In

ADS-5102

DRUG4 trials

Sponsors

Adamas Pharmaceuticals, Inc.

Conditions

DyskinesiaLevodopa Induced Dyskinesia (LID)Levodopa-Induced Dyskinesia (LID)Multiple SclerosisParkinson's DiseaseParkinson's Disease (PD)Walking Impairment

Phase 2

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
CompletedNCT02471222
Adamas Pharmaceuticals, Inc.Multiple Sclerosis, Walking Impairment
Start: 2015-05-31End: 2016-06-30Updated: 2017-08-08

Phase 3

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
CompletedNCT02136914
Adamas Pharmaceuticals, Inc.Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
Start: 2014-05-31End: 2015-12-31Updated: 2018-02-06
Open-Label Safety Study of ADS-5102 in PD Patients With LID
CompletedNCT02202551
Adamas Pharmaceuticals, Inc.Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
Start: 2014-07-31End: 2018-02-28Updated: 2020-10-06
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
CompletedNCT02274766
Adamas Pharmaceuticals, Inc.Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
Start: 2014-10-31End: 2016-03-10Updated: 2018-01-10

Related Papers

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.
2022-03-1814 citations
Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
Neurology and Therapy2021-05-2213 citations
Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
Neurology and Therapy2021-04-1715 citations
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Frontiers in Neurology2021-03-2623 citations
Gocovri Reduces Disruptive Motor Episodes and Improves Function in Parkinson’s Disease Patients With OFF Episodes and Dyskinesia: Analysis of Phase 3 Trial Data (1882)
Neurology2020-04-143 citations
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
2018-04-0148 citations
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
2018-02-2314 citations
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
JAMA Neurology2017-06-12170 citations
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
2017-01-0140 citations